The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Advantages of liquid biopsy-based approaches in Hodgkin lymphoma: capturing tumor heterogeneity
Sven Borchmann, MD, PhD, University of Cologne, Cologne, Germany, comments on the advantages of liquid biopsy in capturing tumor heterogeneity in the context of Hodgkin lymphoma, highlighting its potential to provide information on tumor genetics from multiple sites in the body. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So one of the advantages of liquid biopsy is that we capture really what happens in the whole patient. So when we take a sample of circulating tumor DNA, we get information on the tumor genetics from all different parts where the tumor might be, or in the case of MRD, where the tumor might still be. And that’s different from just having one PET-positive lesion and biopsying it. So the advantage is really that in case we have tumor heterogeneity, we can capture this very well with a liquid biopsy...
So one of the advantages of liquid biopsy is that we capture really what happens in the whole patient. So when we take a sample of circulating tumor DNA, we get information on the tumor genetics from all different parts where the tumor might be, or in the case of MRD, where the tumor might still be. And that’s different from just having one PET-positive lesion and biopsying it. So the advantage is really that in case we have tumor heterogeneity, we can capture this very well with a liquid biopsy. However, one must say in Hodgkin lymphoma, for example, just because we’ve been talking about this before, we don’t know much about whether the tumor is actually different between two different lesions. So I think we might have to study this a bit more to actually make sense of that data. But if we do, and there is maybe emerging information or research that will tell us lymphoma is different between, let’s say, the mediastinum and the axilla. So when we have a lesion there, we can make use of that.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
SB is a founder, shareholder, and managing director of Liqomics and a consultant for Galapagos.
